Londo:
Want to make a few more comments, to further frame my questions.....
MCDE is clearly not a stock that would soar, without considerable good news, in any sector recovery. IMO, your criticisms are very, very valid. I want to make sure that you see that I agree with your commentary as it related to MCDE as a functioning, independent entity.
Some biotech investors focus on fundamental value rather than "story". It hurts sometimes. Like right now. Sometimes, if you pick the wrong stock, the hurt never goes away.
To give you further perspective..... I purchased shares, pre-ICAAC at about $8/share. When it went to $15, I considered it to be significantly overvalued, given the potential for bad news from JNJ, and sold. It is, unfortunately, a stock to trade these days.
The question..... was I making a mistake at $8, or was I wise?
I don't have a ton of bias here, and I have a relatively small position. I do, however, have an interest in your answers. They will help me (and others?) to formulate a strategy here.
Thanks.
Rick |
